News & Updates
Filter by Specialty:
Bimekizumab maintains skin clearance in patients with plaque psoriasis
Maintenance treatment with bimekizumab achieves complete scalp, palmoplantar, or nail clearance in patients with moderate-to-severe plaque psoriasis, according to two phase III trials presented at EADV 2021.
Bimekizumab maintains skin clearance in patients with plaque psoriasis
22 Oct 2021
Baricitinib + standard care may reduce mortality in hospitalized COVID-19 patients
The oral selective Janus kinase 1/2 inhibitor baricitinib, when added to standard of care (SoC), reduced the risk of mortality among adults hospitalized with COVID-19. However, the primary outcome of disease progression was not met in the baricitinib group, results of the phase III COV-BARRIER study showed.
Baricitinib + standard care may reduce mortality in hospitalized COVID-19 patients
21 Oct 2021
Negative upper endoscopy findings in GERD signal lower upper gastrointestinal cancer risk
Negative upper endoscopy findings in patients with gastroesophageal reflux disease (GERD) indicate lower risk of developing upper gastrointestinal cancer, a new study has found.
Negative upper endoscopy findings in GERD signal lower upper gastrointestinal cancer risk
21 Oct 2021
SGLT2i alone or with DPP4 inhibitors prevents hospitalization due to heart failure
Use of sodium glucose co-transporter 2 inhibitors (SGLT2is) either alone or in combination with dipeptidyl peptidase 4 inhibitors (DPP4is) reduces the risk of hospitalization from heart failure (HHF), a study has shown. In contrast, thiazolidinediones alone or in combination with DPP4is increases HHF risk, but glucose-lowering can help reduce HHF.